NYAS Conferences
New York Academy of Sciences
left end
Search
divider divider feedback right end
Annals of the New York Academy of Sciences Annals of the New York Academy of Sciences login

Main

Browse Volumes

Forthcoming Volumes

Annals PrePrints

Annals Extra

E-mail Alerts

Subscriptions & Orders

New Proposals

Author Guidelines

About Annals

Help

Get free Annals volume as a NYAS member: http://www.nyas.org/annalsreaderhw
Issue 1059 coverTumor Progression and Therapeutic Resistance Volume 1059 published December 2005
Ann. N.Y. Acad. Sci. 1059: 86–96 (2005). doi: 10.1196/annals.1339.029
Copyright © 2005 by the New York Academy of Sciences
description | purchase volume purchase this volume

This Volume
Table of Contents
Description
This Article
Full Text
Full Text (PDF)
Services
Similar articles in this journal
Similar articles in PubMed
Alert me to new issues of the journal
Download to citation manager
Citing Articles
Citing Articles via HighWire
Citing Articles via Google Scholar
Google Scholar
Articles by NICOLAIDES, N. C.
Articles by GRASSO, L.
Search for Related Content
PubMed
PubMed Citation
Articles by NICOLAIDES, N. C.
Articles by GRASSO, L.
Morphogenics as a Tool for Target Discovery and Drug Development

NICHOLAS C. NICOLAIDES, WOLFGANG EBEL, BRAD KLINE, QIMIN CHAO, ERIC ROUTHIER, PHILIP M. SASS AND LUIGI GRASSO

Morphotek Inc., Exton, Pennsylvania 19342, USA

Address for correspondence: Nicholas C. Nicolaides, Morphotek Inc., 210 Welsh Pool Road, Exton, PA 19342. Voice: 610-423-6100; fax: 610-423-6199. nicolaides{at}morphotek.com

Mutations in DNA mismatch repair (MMR) genes lead to genetically hypermutable cells. Germline mutations in MMR genes in man have been linked to the genetic predisposition to hereditary nonpolyposis colon cancer and a number of other inherited and sporadic malignancies. The ability to modulate the MMR process (referred to as morphogenics) in model systems offers a powerful tool for generating functional diversity in cells and multicellular organisms via the perpetual genomewide accumulation of randomized point and slippage mutation(s). Morphogenics is a platform process that employs a dominant negative MMR gene to create genetic diversity within defined cellular systems and results in a wide range of phenotypes, thus enabling the development and improvement of pharmaceutical products and the discovery of new pharmaceutical targets. Libraries of morphogenics-derived siblings are generated through random mutagenesis from naturally occurring DNA polymerase-induced mutations that occur during DNA replication. Morphogenic cells are screened in high-throughput assays to identify subclones with desired phenotypes for pathway discovery and/or product development. Morphogenics has been successfully applied to a wide range of hosts, including mammalian cells, transgenic mice, plants, yeast, and bacteria. Manipulation of these systems via morphogenics has led to the discovery of novel disease-associated phenotypes in targeted model systems. Moreover, morphogenics has been successfully applied to antibody-producing cell lines to yield subclones producing antibodies with enhanced binding affinities for therapeutic use, as well as to derive subclones with enhanced titers that are suitable for scaleable manufacturing. The selective manipulation of the MMR process via morphogenics is a platform technology that offers many advantages for the discovery of druggable targets, as well as for the development of novel pharmaceutical products.

Key Words: mismatch repair • mutagenesis • PMS2 • MORPHOGENE • morphogenics • systems biology




This article has been cited by other articles:


Home page
J. Immunol.Home page
C. E. Schaller, C. L. Wang, G. Beck-Engeser, L. Goss, H. S. Scott, M. S. Anderson, and M. Wabl
Expression of Aire and the Early Wave of Apoptosis in Spermatogenesis
J. Immunol., February 1, 2008; 180(3): 1338 - 1343.
[Abstract] [Full Text] [PDF]



footerLeft footerRight